Based on our analysis of the information you provided, we find it interesting that, even though ACCME's reaccreditation process relies almost exclusively on information supplied by the CME providers under review, ACCME still detects a significant number of incidences of noncompliance. It also appears that compliance with ACCME standards still allows CME providers to accommodate the business interests of their commercial sponsors and affords drug companies the ability to target their grant funding at programs likely to support sales of their products. The full extent to which drug companies influence the content of putatively independent CME programs cannot be estimated from the information we currently have.Click here to read the press release and letter. And don't forget to participate in the Medical Meetings magazine survey on this topic -- click here to access.
Wednesday, May 02, 2007
Fasten your seatbelts
The Senate Finance Committe just sent a letter to the ACCME urging "greater oversight by the council" per the press release. An excerpt from the letter: